Effect of bacterial metabolites on microsporidian Nosema ceranae and on its host Apis mellifera.
Nosemosis, a disease caused by a microsporidian infection, is one of the most frequently observed parasitic pathologies affecting adult honeybees. Presently, Nosema ceranae seems to be the main microsporidian infection in Apis mellifera. The antibiotic fumagillin is the only compound available to treat Nosema diseases; however, it is no longer licensed in most EU member states; therefore, the need to identify new molecules/substances prevails. The intent of this paper is to test bacterial metabolites by Bacillus and Enterococcus strains, isolated from bee midgut and honey. The toxicity on bees and the antiparasitic activity on N. ceranae were assessed under laboratory conditions. Results did not yield toxicity for the administered surfactin or bacteriocin concentrations. Spores exposed to direct contact with a particular surfactin revealed a significant infectivity reduction when inoculated on bees. This surfactin, administered ad libitum from the individuals' emergence, led to a significant reduction in parasitosis development when bees were infected with untreated spores 7 days postemergence. Based on the results obtained, one of the surfactins is herein postulated as a molecule capable of reducing N. ceranae development, acting either by direct exposure to purified spores or incorporated into the digestive tract of the bee.
Porrini
Martín P
MP
Arthropods Laboratory FCEyN, UNMdP, Mar del Plata, Argentina. mporrini@mdp.edu.ar
Audisio
M Carina
MC
Sabaté
Daniela C
DC
Ibarguren
Carolina
C
Medici
Sandra K
SK
Sarlo
Edgardo G
EG
Garrido
P Melisa
PM
Eguaras
Martín J
MJ
D000818:Animals; D000935:Antifungal Agents / Q000302:isolation & purification / Q000494:pharmacology* / Q000633:toxicity; D001407:Bacillus / Q000737:chemistry* / Q000302:isolation & purification; D001516:Bees / Q000187:drug effects* / Q000382:microbiology; D004271:DNA, Fungal / Q000737:chemistry / Q000235:genetics; D016983:Enterococcus / Q000737:chemistry* / Q000302:isolation & purification; D041981:Gastrointestinal Tract / Q000382:microbiology; D055666:Lipopeptides / Q000302:isolation & purification / Q000494:pharmacology* / Q000633:toxicity; D008969:Molecular Sequence Data; D016818:Nosema / Q000187:drug effects*; D010456:Peptides, Cyclic / Q000302:isolation & purification / Q000494:pharmacology* / Q000633:toxicity; D017422:Sequence Analysis, DNA
D000935:Antifungal Agents; D004271:DNA, Fungal; D055666:Lipopeptides; D010456:Peptides, Cyclic; C009365:surfactin peptide
Bacteriol Rev. 1977 Jun;41(2):449-74
70202
Bioresour Technol. 2008 Jul;99(11):4603-8
17855083
Res Microbiol. 2009 Apr;160(3):193-9
19358885
Appl Environ Microbiol. 1991 Dec;57(12):3450-5
1785922
Arzneimittelforschung. 1954 Mar;4(3a):161-8
13159718
Int J Food Microbiol. 2007 Jun 10;117(1):43-9
17467096
J Econ Entomol. 2009 Oct;102(5):1729-36
19886435
Appl Environ Microbiol. 2007 Oct;73(20):6331-8
17675417
Int J Food Microbiol. 2001 Feb 15;63(3):235-41
11246907
Microbiol Rev. 1995 Jun;59(2):171-200
7603408
Subcell Biochem. 2008;47:208-20
18512354
J Invertebr Pathol. 2009 Mar;100(3):185-8
19135448
Trends Biotechnol. 2004 Mar;22(3):142-6
15036865
J Invertebr Pathol. 1978 May;31(3):389-91
681774
J Invertebr Pathol. 2008 Jan;97(1):76-8
17651750
Appl Microbiol Biotechnol. 1999 May;51(5):553-63
10390813
Appl Environ Microbiol. 2009 Nov;75(21):6886-9
19734329
J Invertebr Pathol. 2006 Jun;92(2):93-5
16574143
Appl Environ Microbiol. 2005 Jun;71(6):3373-5
15933045
J Invertebr Pathol. 2008 Nov;99(3):342-4
18550078
J Invertebr Pathol. 2007 Sep;96(1):1-10
17428493
J Food Prot. 1999 Jul;62(7):751-5
10419267
J Eukaryot Microbiol. 2005 Sep-Oct;52(5):399-451
16248873
Biologicals. 1997 Sep;25(3):289-97
9324997
Microbiol Res. 2011 Jan 20;166(1):1-13
20116222
J Invertebr Pathol. 2006 Mar;91(3):141-6
16458322